Rimegepant sulfate ODT is under clinical development by Biohaven Pharmaceutical Holding Company and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Rimegepant sulfate ODT’s likelihood of approval (LoA) and phase transition for Psoriasis took place on 31 May 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

In addition, the same event on 31 May 2021 increased Rimegepant sulfate ODT’s LoA and PTSR for Trigeminal Neuralgia (Tic Douloureux).

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Rimegepant sulfate ODT Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Rimegepant sulfate ODT overview

Rimegepant sulfate (Nurtec, Vydura) is an anti-migraine agent. It is formulated as disintegrating tablets and lyophilized tablets for oral route of administration. It is indicated for the acute treatment of migraine with or without aura in adults and also indicated for the preventive treatment of episodic migraine in adults and chronic rhinosinusitis with or without nasal polyps.

Rimegepant is under development for psoriasis, cluster headache, chronic rhinosinusitis, temporomandibular disorder (TMD), acute treatment and prevention of migraine in China and refractory trigeminal neuralgia. The drug candidate is administered as orally dissolving tablet. It is a new chemical entity which acts by targeting calcitonin gene related peptide (CGRP) receptor.

Biohaven Pharmaceutical Holding Company overview

Biohaven Pharmaceutical Holding Company (Biohaven) is a clinical-stage biopharmaceutical company. The company develops late-stage product candidates for neurological diseases. The company develops small molecule CGRP receptor antagonist platform that includes two product candidates such as rimegepant for the acute treatment of migraine, and zavegepant for the prevention of a chronic and episodic migraine. Its glutamate modulation platform includes product candidates such as trigriluzole and BHV-4157 for the treatment of obsessive-compulsive disorder (OCD) and Alzheimer’s disease; BHV-0223 for the treatment of amyotrophic lateral sclerosis (ALS); and BHV-5000 for treating symptoms associated with Rett syndrome and other neuropsychiatric indications. Biohaven is headquartered in New Haven, Connecticut, the US.

Quick View Rimegepant sulfate ODT LOA Data

Report Segments
  • Innovator (NME)
Drug Name
  • Rimegepant sulfate ODT
Administration Pathway
  • Oral
Therapeutic Areas
  • Central Nervous System
  • Ear Nose Throat Disorders
  • Immunology
  • Mouth and Dental Disorders
  • Undisclosed
Key Developers
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.